These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38331925)

  • 21. Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.
    Zahr RS; Hankins JS; Kang G; Li C; Wang WC; Lebensburger J; Estepp JH
    Am J Hematol; 2019 Jan; 94(1):E27-E29. PubMed ID: 30359463
    [No Abstract]   [Full Text] [Related]  

  • 22. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in Transcranial Doppler Flow Velocities in Children with Sickle Cell Disease: The Impact of Hydroxyurea Therapy.
    Adegoke SA; Macedo-Campos RS; Braga JAP; Figueiredo MS; Silva GS
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):425-431. PubMed ID: 29056404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia.
    Keikhaei B; Yousefi H; Bahadoram M
    Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic review on hydroxyurea therapy for sickle cell disease in India.
    Pandey A; Kaur H; Borah S; Khargekar N; Karra VK; Adhikari T; Jain D; Madkaikar M
    Indian J Med Res; 2022 Aug; 156(2):299-311. PubMed ID: 36629190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
    Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK
    Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 29. Emerging drugs for sickle cell anemia.
    Singh PC; Ballas SK
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):47-61. PubMed ID: 25431087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What drives transcranial Doppler velocity improvement in paediatric sickle cell anaemia: analysis from the Sickle Cell Clinical Research and Intervention Program (SCCRIP) longitudinal cohort study.
    Estepp JH; Cong Z; Agodoa I; Kang G; Ding J; McCarville MB; Hankins JS; Wang WC
    Br J Haematol; 2021 Jul; 194(2):463-468. PubMed ID: 34131902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.
    Cunningham-Myrie C; Abdulkadri A; Waugh A; Bortolusso Ali S; King LG; Knight-Madden J; Reid M
    Pediatr Blood Cancer; 2015 Oct; 62(10):1862-4. PubMed ID: 25929458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea or chronic exchange transfusions in patients with sickle cell disease: role of transcranial Doppler ultrasound in stroke prophylaxis.
    Suliman H; Wali Y; Al Saadoon M; Zechariah M; William RR; Gujjar A; Pathare A
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):42-4. PubMed ID: 19125086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease.
    Darshana T; Rees D; Premawardhena A
    Orphanet J Rare Dis; 2021 Mar; 16(1):148. PubMed ID: 33757549
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
    Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
    Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial.
    Rankine-Mullings A; Reid M; Soares D; Taylor-Bryan C; Wisdom-Phipps M; Aldred K; Latham T; Schultz WH; Knight-Madden J; Badaloo A; Lane A; Adams RJ; Ware RE
    Br J Haematol; 2021 Nov; 195(4):612-620. PubMed ID: 34291449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.
    Abdullahi SU; Jibir BW; Bello-Manga H; Gambo S; Inuwa H; Tijjani AG; Idris N; Galadanci A; Hikima MS; Galadanci N; Borodo A; Tabari AM; Haliru L; Suleiman A; Ibrahim J; Greene BC; Ghafuri DL; Rodeghier M; Slaughter JC; Kirkham FJ; Neville K; Kassim A; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR
    Lancet Haematol; 2022 Jan; 9(1):e26-e37. PubMed ID: 34971579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.
    DeBaun MR
    Expert Rev Hematol; 2014 Dec; 7(6):767-73. PubMed ID: 25242414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
    Niihara Y; Miller ST; Kanter J; Lanzkron S; Smith WR; Hsu LL; Gordeuk VR; Viswanathan K; Sarnaik S; Osunkwo I; Guillaume E; Sadanandan S; Sieger L; Lasky JL; Panosyan EH; Blake OA; New TN; Bellevue R; Tran LT; Razon RL; Stark CW; Neumayr LD; Vichinsky EP;
    N Engl J Med; 2018 Jul; 379(3):226-235. PubMed ID: 30021096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.